JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 6869.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Sysmex Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sysmex Corporation’s forward annual dividend is ¥20 per share, paid annual. The forward yield is 1.03% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Sysmex Corporation’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of ¥15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sysmex Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:48 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 |
|---|
| May 14, 2025 |
| ¥18-23.26% vs estimate |
| ¥141.78B-3.19% vs estimate |
| Q3 2025 | Feb 12, 2025 | ¥27+18.97% vs estimate | ¥124.39B-2.5% vs estimate |
|---|
| Q2 2025 | Nov 6, 2024 | ¥24+5.77% vs estimate | ¥130.53B+1.83% vs estimate |
|---|
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥6,651+¥180 (+2.78%)
Takeda Pharmaceutical Company Limited’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
¥22,035-¥885 (-3.86%)
HORIBA, Ltd.’s quoted price sits in the upper half of its reported 52-week range, 26.79% below the high.
¥6,951-¥285 (-3.94%)
JEOL Ltd.’s quoted price sits in the upper half of its reported 52-week range, 24.89% below the high.
¥2,532+¥15 (+0.58%)
Ship Healthcare Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.83% below the high.
¥3,936+¥114 (+2.98%)
H.U. Group Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.46% below the high.
¥1,415+¥52 (+3.82%)
PHC Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 16.47% below the high.
¥3,835+¥65 (+1.72%)
BML, Inc.’s quoted price sits in the lower half of its reported 52-week range, 12.54% below the high.
